Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
When a foreign cosmetic facility is budgeting for compliance with the Modernization of Cosmetics Regulation Act (MoCRA), what key factors determine the cost of retaining an FDA U.S. Agent? While speci...
As medical device manufacturers plan for 2026 EU MDR compliance, what comprehensive framework should be used to select an external Person Responsible for Regulatory Compliance (PRRC) service, moving b...
With the final registration deadline for Turkey's KKDIK (REACH) regulation set for December 31, 2026, how should non-Turkish manufacturers strategically evaluate and select an Only Representative (OR)...
For manufacturers developing a Class II in vitro diagnostic (IVD), such as a prognostic test for liver disease progression (21 CFR 862.1622) or a therapeutic drug monitoring assay like a sirolimus tes...
While the Modernization of Cosmetics Regulation Act (MoCRA) establishes a clear requirement for foreign cosmetic facilities to designate a U.S. Agent, determining the associated cost is not straightfo...
In light of recent MDCG guidance providing greater clarity on the role of the Person Responsible for Regulatory Compliance (PRRC), how should a medical device manufacturer, especially a small or micro...
For non-EU medical device manufacturers navigating compliance with the EU MDR, the regulation's requirements regarding substances can trigger obligations under the REACH regulation. When a manufacture...
When expanding into international markets, medical device manufacturers must navigate a complex landscape of both product-specific and general business regulations. For example, a company developing a...
For manufacturers of electronic medical devices, such as certain in-vitro diagnostic systems or therapeutic equipment, navigating global regulations extends beyond primary health authorities. In marke...
Given the increased scrutiny on the Person Responsible for Regulatory Compliance (PRRC) role under the EU MDR, particularly following recent MDCG guidance that clarifies expectations for qualification...
When non-EU manufacturers plan for European market access under the Medical Device Regulation (MDR), selecting a qualified European Authorized Representative (AR) is a critical compliance step. The AR...
Given that an agent's purpose is to generate educational content specifically on medical device regulatory topics (such as FDA 510(k), De Novo, or EU MDR), how should it address a query that is fundam...
With significant revisions to the EU WEEE Directive anticipated for 2026, medical device manufacturers face increasing complexity in managing their environmental compliance. When selecting or re-evalu...
With significant revisions anticipated for the primary international standard governing the biological evaluation of medical devices, how should manufacturers proactively adapt their biocompatibility ...
For non-EU manufacturers of chemical substances planning for European market access through 2026, what are the critical legal, operational, and strategic requirements when appointing a REACH Only Repr...
When developing a Software as a Medical Device (SaMD) intended to function as a retinal diagnostic tool, what are the key regulatory and validation considerations sponsors should address to align with...
With significant updates to the EU’s environmental regulations, including the WEEE Directive and new Circular Economy initiatives expected around 2026, how should a medical device manufacturer strateg...
Given the evolving landscape of international standards like the ISO 10993 series, how should medical device sponsors strategically plan a biocompatibility evaluation for a U.S. FDA submission anticip...
As global medical device regulations evolve, the responsibilities of a manufacturer's designated in-country representative become increasingly complex. For non-domestic manufacturers, this entity is t...
When a medical device manufacturer plans to enter the European market, selecting a European Authorized Representative (EC-REP) is a critical compliance step under the EU MDR. Beyond comparing basic se...